$PSNL News

Personalis Highlights Cancer-Detection Data Across Multiple Tumor Types

Personalis: Initiating Coverage Of Cancer Testing Biotech With A Buy Rating

Personalis to Present New Cancer Detection Data at Major Oncology Conference

US Agency Broadens Coverage Of Personalis Breast Cancer Test

Morgan Stanley Maintains Equal-Weight on Personalis, Lowers Price Target to $9

BTIG Maintains Buy on Personalis, Lowers Price Target to $11

Personalis, Inc. (PSNL) Q1 2026 Earnings Call Transcript

Personalis (NASDAQ:PSNL) Volume Surge Can't Mask Q1 Miss as Losses Widen

Personalis Affirms FY2026 Sales Guidance of $78.000M-$80.000M vs $78.758M Est

Personalis Q1 EPS $(0.29) Misses $(0.27) Estimate, Sales $15.472M Beat $14.483M Estimate

Personalis Presents NeXT Personal ctDNA Data At AACR 2026 Showing 100% Sensitivity In Colorectal Cancer Monitoring

Personalis Showcases New Cancer Test To Track Treatment Resistance In Real Time

Morgan Stanley Lowers Personalis (PSNL) Price Target to $10

Personalis Appoints Dr. Richard Chen as President to Further Accelerate MRD Adoption

Personalis Announces New Publication Advancing Neoadjuvant Treatment Monitoring in Breast Cancer with NeXT Personal®

Personalis Announces The Publication Of PREDICT-DNA Study In The Journal Of Clinical Oncology, Showing That Ultrasensitive Molecular Residual Disease Testing With Next Personal Can Perform Better Than Current Standard Approaches In Predicting Patient Outcomes Following Neoadjuvant Therapy

Morgan Stanley Maintains Equal-Weight on Personalis, Lowers Price Target to $10

Personalis, Inc. Q4 2025 Earnings Call Summary

Personalis Q4 Earnings Call Highlights

Breaking Down Personalis: 5 Analysts Share Their Views